TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22480758

Group type: COMPARATOR
Intervention: 8×B(esc) group
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: 6×B(esc) group
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: 8×B(14) group
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: PET-guided radiotherapy
Number of subjects: 2182
Study: 19944580

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18035195

Group type: EXPERIMENTAL
Intervention: Ibutilide 0.005 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibutilide 0.01 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibutilide 0.02 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibutilide 0.5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibutilide 0.75 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibutilide 1.0 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ibutilide (all doses)
Number of subjects: 40
Study: 16223390

Group type: EXPERIMENTAL
Intervention: J‐wire tip directed downward
Number of subjects: 140

Group type: COMPARATOR
Intervention: J‐wire tip directed upward
Number of subjects: 140
Study: 12042266

Group type: EXPERIMENTAL
Intervention: Trilostane
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Trilostane 1080 mg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Trilostane 720 mg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Trilostane + Danazol
Number of subjects: 116
Study: 10214664

Group type: EXPERIMENTAL
Intervention: New corticosteroid drug
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 7833731

Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Metformin (in obese subjects)
Number of subjects: 2520

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 2520
Study: 2226910

Group type: EXPERIMENTAL
Intervention: Norethindrone 1 mg/mestranol 0.05 mg/d (group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 48
Study: 999082

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 366

Group type: COMPARATOR
Intervention: Spinal or general anesthesia
Number of subjects: 366
Study: 31159548

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy with automated instillation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (standard negative pressure therapy)
Number of subjects: 41
Study: 27513627

Group type: EXPERIMENTAL
Intervention: iPad administration of ICIQ questionnaires
Number of subjects: 448

Group type: COMPARATOR
Intervention: Telephone administration of ICIQ questionnaires
Number of subjects: 448

Group type: COMPARATOR
Intervention: Paper administration of ICIQ questionnaires
Number of subjects: 448
Study: 25533601

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program (3 sets of 10 to 12 leg extensions at 70% of estimated 1-repetition maximum thrice weekly for 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonexercise control (usual physical activity)
Number of subjects: 38
Study: 23604170

Group type: EXPERIMENTAL
Intervention: Microcone disc stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flat disc stimulation
Number of subjects: 12
Study: 20078697

Group type: EXPERIMENTAL
Intervention: One-step self-etch bonding agent
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two-step total-etch bonding agent
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unetched-cavity control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intact-teeth control group
Number of subjects: 40
Study: 18328039

Group type: EXPERIMENTAL
Intervention: Biventricular pacemaker in patients with no AF history (G1)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Biventricular pacemaker in patients with history of paroxysmal/persistent AF (G2)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Before AF onset
Number of subjects: 410

Group type: COMPARATOR
Intervention: During persistent AF
Number of subjects: 410
Study: 15672116

Group type: EXPERIMENTAL
Intervention: High calcium and normal protein (HC/NP: 1800 mg calcium, 15% of energy from protein)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low calcium and normal protein (LC/NP: 500 mg calcium, 15% of energy from protein)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High calcium and high protein (HC/HP: 1800 mg calcium, 23% of energy from protein)
Number of subjects: 10
Study: 12574569

Group type: EXPERIMENTAL
Intervention: Surgery for 50% to 69% stenosis (n=646)
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: Surgery for 70% to 99% stenosis without near occlusion (n=429)
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: Surgery for near occlusion (n=125)
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: Surgery for <30% stenosis (n=1321)
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: Surgery for 30% to 49% stenosis (n=478)
Number of subjects: 3018
Study: 10564627

Group type: EXPERIMENTAL
Intervention: Personalized risk notification and tailored materials
Number of subjects: 901
Study: 8708586

Group type: EXPERIMENTAL
Intervention: Intensive advice + pravastatin
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Usual advice + pravastatin
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Intensive advice (no drug)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Usual advice (no drug)
Number of subjects: 681
Study: 1662883

Group type: EXPERIMENTAL
Intervention: Temafloxacin 400 mg
Number of subjects: 279

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg
Number of subjects: 279
Study: 6813126

Group type: EXPERIMENTAL
Intervention: NTG-TTS (transdermal therapeutic system for nitroglycerin)
Number of subjects: 13
Study: 30185767

Group type: EXPERIMENTAL
Intervention: Telephone/WeChat preoperative health education
Number of subjects: 426

Group type: COMPARATOR
Intervention: Routine preoperative education
Number of subjects: 426
Study: 28269510

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of subthalamic nucleus (STN‐DBS)
Number of subjects: 15
Study: 24997007

Group type: EXPERIMENTAL
Intervention: Web-based psychological capital intervention (four training sessions over 4 weeks)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 354
Study: 22169672

Group type: EXPERIMENTAL
Intervention: 1-stage procedure
Number of subjects: 11

Group type: COMPARATOR
Intervention: 2-stage procedure
Number of subjects: 11
Study: 20225082

Group type: EXPERIMENTAL
Intervention: Rhythmic handgrip exercise at 60% of maximum voluntary contraction for 20 min/day, 5 days/week for 4 weeks
Number of subjects: 11
Study: 19110786

Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel maintenance dose
Number of subjects: 117

Group type: COMPARATOR
Intervention: 75 mg clopidogrel maintenance dose (control)
Number of subjects: 117
Study: 17130267

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonatorvastatin therapy
Number of subjects: 66
Study: 12939009

Group type: EXPERIMENTAL
Intervention: Single-stage implants with screw-retained restorations
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-stage implants with cemented restorations
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-stage implants in completely edentulous patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-stage implants in partially edentulous patients
Number of subjects: 51
Study: 11039684

Group type: EXPERIMENTAL
Intervention: Child‐focused cognitive‐behaviour therapy (CBT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CBT plus parent involvement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 50
Study: 8900982

Group type: EXPERIMENTAL
Intervention: Optokinetic drum rotation for 12 minutes
Number of subjects: 49
Study: 1825144

Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain response after 4 weeks
Number of subjects: 0
Study: 6661342

Group type: EXPERIMENTAL
Intervention: Propranolol administration during exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo periods
Number of subjects: 9
Study: 30951598

Group type: EXPERIMENTAL
Intervention: Active Blood Flow Restriction Training (BFRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo Blood Flow Restriction Training (standard of care)
Number of subjects: 60
Study: 28990807

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy for tinnitus
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study: 26238576

Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 659

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study: 24569045

Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/d
Number of subjects: 139

Group type: COMPARATOR
Intervention: Escitalopram 10-20 mg/d
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 23257370

Group type: EXPERIMENTAL
Intervention: pPCI with thrombectomy (Group T)
Number of subjects: 208
Study: 20061838

Group type: EXPERIMENTAL
Intervention: Gabapentin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin in combination therapy with two antihistamines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpheniramine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpheniramine in combination with two antihistamines
Number of subjects: 0
Study: 16984938

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (60 mg daily for the first week and 40 mg daily for the second week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15886179

Group type: EXPERIMENTAL
Intervention: Organizations implementing more HIPAA Privacy Rule requirements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Organizations not implementing HIPAA Privacy Rule requirements
Number of subjects: 0
Study: 12944994

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant cytotoxic therapy
Number of subjects: 0
Study: 10567755

Group type: EXPERIMENTAL
Intervention: Tripedal stance on three remaining holds for vertical forces
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Bipedal stance on two laterally opposite holds (left foot and left holds) for horizontal forces
Number of subjects: 1
Study: 8949825

Group type: EXPERIMENTAL
Intervention: Combination of edrophonium 1 mg kg‐1 and exogenous PCHE equivalent to activity present in 25 ml kg‐1 of human plasma
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (spontaneous recovery)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 (group ED)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exogenous PCHE equivalent to activity present in 25 ml kg‐1 of human plasma (group PCHE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 and exogenous PCHE (combination group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Exogenous PCHE (group PCHE)
Number of subjects: 40
Study: 2024224

Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanate
Number of subjects: 99

Group type: COMPARATOR
Intervention: Gentamicin and clindamycin
Number of subjects: 99
Study: 7014073

Group type: EXPERIMENTAL
Intervention: 400 mg doxpicomine
Number of subjects: 43

Group type: COMPARATOR
Intervention: 8 mg morphine
Number of subjects: 43

Group type: COMPARATOR
Intervention: 4 mg morphine
Number of subjects: 43
Study: 31833868

Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis during the third trimester
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: No antepartum heparin prophylaxis
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Venous thromboembolism
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Comparison of outcomes
Number of subjects: 145
Study: 31301146

Group type: EXPERIMENTAL
Intervention: Adjunctive PAD (red LED, 635 nm, photosensitive dye, 0.01% tolonium chloride)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no adjunctive PAD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adjunctive PAD
Number of subjects: 20
Study: 28160084

Group type: EXPERIMENTAL
Intervention: N‐3 PUFA (2330 mg day‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 30
Study: 27969041

Group type: EXPERIMENTAL
Intervention: Daily journal writing as reinforcement for resourcefulness training (RT) over a four-week period.
Number of subjects: 0
Study: 24438517

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (text-message and voucher component)
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 2550
Study: 22406990

Group type: EXPERIMENTAL
Intervention: BMS + high-dose oral sirolimus (initial dose of 15 mg, followed by 6 mg/day for four weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BMS + low-dose sirolimus (6 mg followed by 2 mg daily for four weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: BMS without sirolimus
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (BMS + high-dose sirolimus, BMS + low-dose sirolimus, BMS without sirolimus)
Number of subjects: 45
Study: 19054608

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNTA) treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no overactive bladder symptoms)
Number of subjects: 21
Study: 17876365

Group type: EXPERIMENTAL
Intervention: SCS at T5‐T6 region
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SCS at T1‐T2 region
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (SCS off) during CPT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SCS at T5‐T6 region during CPT
Number of subjects: 8
Study: 15236635

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.25%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.32%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.40%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.50%
Number of subjects: 50

Group type: COMPARATOR
Intervention: bupivacaine 0.25%
Number of subjects: 50
Study: 12688173

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (non-CPB)
Number of subjects: 144
Study: 9829604

Group type: EXPERIMENTAL
Intervention: Continuous nasogastric infusion of liquid feeding (4.2 kJ/mL, energy provision 1 x the initial predicted basal metabolic rate; 3 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous nasogastric infusion of colored water (2 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous nasogastric infusion of liquid feeding (4.2 kJ/mL)
Number of subjects: 6
Study: 7917576

Group type: EXPERIMENTAL
Intervention: QCT (Quantitative Computed Tomography)
Number of subjects: 45

Group type: COMPARATOR
Intervention: DPA (Dual Energy Photon Absorptiometry)
Number of subjects: 45
Study: 2780070

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg for upper limb pain, 20 mg for lower limb pain)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 16
Study: 1108735

Group type: EXPERIMENTAL
Intervention: Polyinosinic‐polycytidylic acid (In‐Cn)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDU (Idoxuridine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis with In‐Cn
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDU or In‐Cn
Number of subjects: 0
Study: 31399446

Group type: EXPERIMENTAL
Intervention: Xuanbi antong granules (XAG)
Number of subjects: 300

Group type: COMPARATOR
Intervention: XAG placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: XAG
Number of subjects: 300
Study: 29322923

Group type: EXPERIMENTAL
Intervention: Linear polynomial (degree 1 polynomial) using correlation analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear polynomial (degree 1 polynomial) using apoptosis pathway gene selection
Number of subjects: 0
Study: 25732032

Group type: EXPERIMENTAL
Intervention: Palliative treatment (use of aspirin and analgesics only, no reperfusion)
Number of subjects: 45091

Group type: COMPARATOR
Intervention: Conservative treatment (any treatment including antithrombotics or anticoagulants, but no reperfusion)
Number of subjects: 45091

Group type: COMPARATOR
Intervention: Reperfusion treatment (thrombolysis and/or percutaneous coronary intervention)
Number of subjects: 45091

Group type: EXPERIMENTAL
Intervention: Palliative treatment
Number of subjects: 45091
Study: 23788306

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) bolus of GP IIb/IIIa inhibitor
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus of GP IIb/IIIa inhibitor
Number of subjects: 77
Study: 21464382

Group type: EXPERIMENTAL
Intervention: Installation of multiple passive measures (eg, stair gates, cabinet locks, and smoke detectors)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 355
Study: 19187417

Group type: EXPERIMENTAL
Intervention: Occupational and physical therapy sessions to instruct participants in compensatory strategies, home modifications, home safety, fall recovery techniques, and balance and muscle strength exercises.
Number of subjects: 319

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 319
Study: 16457132

Group type: EXPERIMENTAL
Intervention: Tolperisone (300-900 mg daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tolperisone
Number of subjects: 120
Study: 15544685

Group type: EXPERIMENTAL
Intervention: Decision aid booklet for menorrhagia
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Pre-trial group (not specified as intervention or control)
Number of subjects: 363
Study: 11408847

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6-g load then 2 g/hr)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (lactated Ringer's solution)
Number of subjects: 22
Study: 9312708

Group type: EXPERIMENTAL
Intervention: 2.7 mm Polypin
Number of subjects: 183

Group type: COMPARATOR
Intervention: Metal implants
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Polyactide implants
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Orientruded polyactide screws
Number of subjects: 183
Study: 8358527

Group type: EXPERIMENTAL
Intervention: CO2 laser ablation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon‐alpha
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CO2 laser ablation plus intramuscular interferon‐alpha
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study: 3117084

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) administered to the nasal mucosa 30 min before provocation with histamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clemastine administered to the nasal mucosa 30 min before provocation with histamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketotifen administered to the nasal mucosa 30 min before provocation with histamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline control solution) administered prior to provocation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG), clemastine, and ketotifen administered to the nasal mucosa 30 min before provocation with allergen
Number of subjects: 0
Study: 30968235

Group type: EXPERIMENTAL
Intervention: Music intervention for 3 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 56
Study: 28318767

Group type: EXPERIMENTAL
Intervention: 4CMenB and MenC-CRM
Number of subjects: 251

Group type: COMPARATOR
Intervention: MenC-CRM alone
Number of subjects: 251
Study: 25433046

Group type: EXPERIMENTAL
Intervention: Over-the-head two-thumb encircling technique (OTTT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two-finger technique (TFT)
Number of subjects: 50
Study: 23394492

Group type: EXPERIMENTAL
Intervention: Plasmacytoid carcinoma (PUC)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Urothelial carcinoma (UC)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Micropapillary carcinoma (MPC)
Number of subjects: 205
Study: 21057336

Group type: EXPERIMENTAL
Intervention: Short-term inpatient psychotherapeutic support (n=59)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Long-term outpatient psychotherapeutic support (n=54)
Number of subjects: 113
Study: 17925050

Group type: EXPERIMENTAL
Intervention: Slow-release vitamin C tablets (500 mg/d) and vitamin E (182 mg/d) for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Well-nourished subjects consuming 600 g fruits and vegetables or equivalent vitamins and minerals for 24 days
Number of subjects: 0
Study: 16194620

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance training program twice a week for five months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 43
Study: 15271002

Group type: EXPERIMENTAL
Intervention: Foreground object presented in a semantically consistent setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Background presented with a semantically consistent foreground object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objects presented in isolation (without backgrounds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Backgrounds presented without foreground objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both objects and backgrounds reported together
Number of subjects: 0
Study: 10786405

Group type: EXPERIMENTAL
Intervention: Sertaconazole monodose vaginal suppository only (group O)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Sertaconazole monodose vaginal suppository combined with sertaconazole cream applied to the vulvar area for 7 days (group OC)
Number of subjects: 77